Of the 80 solid tumor cases in which liquid biopsy (LB) was performed using Guardant360 in the PROFILE study, nine were lung cancer cases. Here, we review three cases in which LB was useful in diagnosing ALK fusion-positive lung cancer, selecting sequential ALK-tyrosine kinase inhibitors, confirming uncommon EGFR mutations, and receiving biomarker-compatible therapy.

中文翻译：

---

使用液体活检（血浆）基于基因组分析治疗晚期肺癌：三例回顾

在 PROFILE 研究中使用 Guardant360 进行液体活检 (LB) 的 80 例实体瘤病例中，有 9 例是肺癌病例。在这里，我们回顾了 LB 可用于诊断ALK融合阳性肺癌、选择连续 ALK-酪氨酸激酶抑制剂、确认不常见的EGFR突变和接受生物标志物兼容治疗的三例病例。